Sagar Sardesai
Overview
Explore the profile of Sagar Sardesai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Grimm M, Radcliff L, Giles M, Nash R, Holley E, Panda S, et al.
J Clin Med
. 2022 Jul;
11(14).
PMID: 35887755
Survivors of advanced breast cancer (ABC), also known as metavivors, are often left with fewer treatment options in the landscape of a cure culture. Metavivors have unique psychosocial and physical...
12.
OShaughnessy J, Brufsky A, Rugo H, Tolaney S, Punie K, Sardesai S, et al.
Breast Cancer Res Treat
. 2022 May;
195(2):127-139.
PMID: 35545724
Purpose: Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a proprietary hydrolyzable linker. In the ASCENT study, SG improved survival versus single-agent...
13.
Sukumar J, Vaughn J, Tegge A, Sardesai S, Lustberg M, Stein J
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267441
Obesity in breast cancer (BC) survivors is associated with increased mortality. Delay discounting (DD) is a behavioral economic measure of how individuals value future outcomes. Higher DD correlates with obesity...
14.
Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens J, Suresh A, et al.
Eur J Breast Health
. 2021 Oct;
17(4):371-377.
PMID: 34651117
Objective: Leptomeningeal carcinomatosis (LMC), a common complication of advanced malignancies, is associated with high morbidity and mortality, yet diagnosis and treatment decisions remain challenging. This study describes the diagnostic and...
15.
Sukumar J, Quiroga D, Kassem M, Grimm M, Shinde N, Appiah L, et al.
Breast Cancer Res Treat
. 2021 Sep;
190(2):183-188.
PMID: 34498153
Purpose: Adjuvant ovarian function suppression (OFS) in premenopausal hormone receptor (HR) positive breast cancer (BC) improves survival. Adherence to adjuvant gonadotropin-releasing hormone analogs (GnRHa) remains a challenge and is associated...
16.
Handy C, Wesolowski R, Gillespie M, Lause M, Sardesai S, Williams N, et al.
Breast Cancer (Auckl)
. 2021 Sep;
15:11782234211037421.
PMID: 34483661
Purpose: Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma...
17.
Blow T, Hyde P, Falcone J, Neinstein A, Vasan N, Chitkara R, et al.
Integr Cancer Ther
. 2021 Jul;
20:15347354211032283.
PMID: 34259084
Alpelisib is a α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), PIK3CA-mutated,...
18.
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, et al.
BMC Cancer
. 2021 May;
21(1):568.
PMID: 34006255
Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus...
19.
Sukumar J, Kassem M, Agnese D, Pilarski R, Ramaswamy B, Sweet K, et al.
Breast Cancer Res Treat
. 2021 Jan;
186(2):569-575.
PMID: 33507482
Background: Concurrent germline (g) pathogenic variants related to hereditary breast cancer represent a rare occurrence. While double heterozygosity in gBRCA1 and gBRCA2 has been reported in the past, herein we...
20.
Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, et al.
Cardiooncology
. 2020 Dec;
6(1):26.
PMID: 33292843
Background: Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor...